<div><div></div><div>Celcuity completed a $575 million offering of 0.250% Convertible Senior Notes due 2032, producing approximately $557 million in net proceeds. The notes, convertible at an initial price of about $124.53 per share, were issued under an underwriting agreement with leading banks and governed by a supplemental indenture executed June 8, 2026. Concurrently, Celcuity retired its existing term loan facility by paying roughly $137.5 million, eliminating related obligations. Management expects the refinancing to lower financing costs and support clinical, commercial, and general corporate initiatives.New agreement details:<ul><li>Agreement type: Underwriting agreement for 0.250% convertible senior notes due 2032</li><li>Counterparty: Jefferies; J.P. Morgan Securities; TD Securities (USA); Guggenheim Securities, as representatives of the underwriters</li><li>Signed / Effective: Jun 03 2026 / Jun 08 2026</li><li>Duration / Termination: Through Aug 01 2032</li><li>Reason: Refinance debt and fund growth initiatives</li></ul>Terminated agreement details:<ul><li>Agreement terminated: Amended and Restated Loan and Security Agreement (term loans)</li><li>Counterparty: Oxford Finance; Innovatus Life Sciences Lending Fund I and other lenders</li><li>Original agreement date: May 30 2024</li><li>Termination date: Jun 08 2026</li><li>Termination type: Early</li><li>Reason: Refinanced with convertible notes and reduce interest burden</li></ul>Original SEC Filing: Celcuity Inc. [ CELC ] - 8-K - Jun. 08, 2026<section>Disclaimer<div>This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.</div></section></div></div>

CELC

Celcuity raised $575 million via 0.25% convertible senior notes due 2032, netting $557 million. Proceeds were used to retire a $137.5 million term loan facility, reducing financing costs. The notes are convertible at ~$124.53 per share. Management expects the refinancing to support clinical and commercial initiatives.

TradingView

Celcuity

Jefferies Financial

JPMorgan Chase

Toronto Dominion Bank

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

Celcuity Raises $575 Million in 0.25% Convertible Notes Due 2032; Net Proceeds $557 Million